BMC cancer · 2026
Eligibility criteria and study phase limit racial/ethnic enrollment in oncology clinical trials.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arizpe Angel, Nieva Jorge, Pickering Trevor A, Liu Lihua, Scampavia Lauren, Ferrin Jenny, Farias Albert J
Аннотация
BACKGROUND: Racial/ethnic minority enrollment in oncological therapeutic clinical trials (TCT) remains low. Thus, we explored whether TCTs' restrictiveness enrollment criteria and phase were associated with racial/ethnic minority enrollment.
METHODS: We analyzed cross-sectional (2016-2023) enrollment data and protocols from oncology TCTs completed at a large urban medical research institution. Two reviewers assessed eligibility restrictiveness using ASCO and Friends of Cancer Research recommendations. Trials received a score (0-8) based on criteria related to brain metastases, infectious diseases (HIV, hepatitis B/C), organ dysfunction (cardiac, liver, kidney), and prior or concurrent malignancies; those with scores above the 75th percentile were classified as restrictive (score > 4). Trial phase was categorized as early (I/II) or late (III/IV). Participants (n = 876) from 144 TCTs were classified as minority (Hispanic, Black, American Indian/Alaska Native, Native Hawaiian/Pacific Islander) or non-minority per NIH definitions. Multivariable Poisson GEE models, adjusting for age, sex, trial timing relative to ASCO/Friends recommendations, and sponsor type, explore these associations.
RESULTS: Completed TCTs were most restrictive in excluding patients with a prior or concurrent malignancy(73%), HIV(59%), and/or liver dysfunction(53%). Of the 876 trial participants, 32% were racial/ethnic minorities, and only 17% were enrolled in restrictive TCTs. Restrictive TCTs had 31%(RR=0.69, 95%CI=0.50-0.95) and early-phase TCTs had 34%(RR =0.66, 95%CI=0.52-0.78) lower risk of enrolling racial/ethnic minority participants compared to standard and later-phase TCTs, respectively.
CONCLUSIONS: TCT studies with restrictive enrollment eligibility criteria and early-phase studies were less likely to enroll racial/ethnic minority participants. Underscoring that enrollment eligibility criteria is a barrier that may hinder minority enrollment.
METHODS: We analyzed cross-sectional (2016-2023) enrollment data and protocols from oncology TCTs completed at a large urban medical research institution. Two reviewers assessed eligibility restrictiveness using ASCO and Friends of Cancer Research recommendations. Trials received a score (0-8) based on criteria related to brain metastases, infectious diseases (HIV, hepatitis B/C), organ dysfunction (cardiac, liver, kidney), and prior or concurrent malignancies; those with scores above the 75th percentile were classified as restrictive (score > 4). Trial phase was categorized as early (I/II) or late (III/IV). Participants (n = 876) from 144 TCTs were classified as minority (Hispanic, Black, American Indian/Alaska Native, Native Hawaiian/Pacific Islander) or non-minority per NIH definitions. Multivariable Poisson GEE models, adjusting for age, sex, trial timing relative to ASCO/Friends recommendations, and sponsor type, explore these associations.
RESULTS: Completed TCTs were most restrictive in excluding patients with a prior or concurrent malignancy(73%), HIV(59%), and/or liver dysfunction(53%). Of the 876 trial participants, 32% were racial/ethnic minorities, and only 17% were enrolled in restrictive TCTs. Restrictive TCTs had 31%(RR=0.69, 95%CI=0.50-0.95) and early-phase TCTs had 34%(RR =0.66, 95%CI=0.52-0.78) lower risk of enrolling racial/ethnic minority participants compared to standard and later-phase TCTs, respectively.
CONCLUSIONS: TCT studies with restrictive enrollment eligibility criteria and early-phase studies were less likely to enroll racial/ethnic minority participants. Underscoring that enrollment eligibility criteria is a barrier that may hinder minority enrollment.